coronary artery Disease. Atherosclerotic heart disease
Conditions
Interventions
Intervention 1: Intervention group: receiving omega 3 capsule (two 2 gr capsule two times daily, total 4 gr) for 8 weeks. Intervention 2: Intervention group: receiving omega 3 capsule (two 2 gr capsul
Treatment - Drugs
Placebo
Intervention group: receiving omega 3 capsule (two 2 gr capsule two times daily, total 4 gr) for 8 weeks
Intervention group: receiving omega 3 capsule (two 2 gr capsule two times daily, total 4 gr) and 1 capsule vitamin E(400 IU)for 8 weeks
control group: receiving placebo capsule contain: omega 3 placebo capsule (two 2 gr capsule two times daily, total 4 gr) and 1 placebo of vitamin E(400 IU)for 8 weeks
Sponsors
tehran university of medical sciences
Eligibility
Sex/Gender
Male
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ? BMI less than 30 ? aged 65-45 years ? More than 50% of patients with at least one coronary artery stenosis confirmed by angiography in three months ? Lack of PPAR? agonist drugs such Tyazvlydyn Dion (TZDs), and fiber and taking angiotensin receptor type 1 blockers and inhibitors of non-ACE, ? willingness to cooperate Criteria excluded: ? kidney disease, liver disease, diabetes, cancer, thyroid disorders, according to the patient's medical history ? smoking (at least 5 threads in the last 6 months) ? omega-3 supplements or fish oil and vitamin E for three months ? Allergy and sensitivity to fish oil ? Lack of cooperation is likely to continue. Mbar excluded Any drastic changes in diet (the doctor, the patient himself)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gene expression of adiponectin in PBMC. Timepoint: Baseline, After8 weeks. Method of measurement: Realtime PCR.;Gene expression of adiponectin receptors , R1 and R2 in PBMC. Timepoint: Baseline , after 8 weeks. Method of measurement: Realtime PCR.;Gene expression of PPAR gamma in PBMC. Timepoint: Baseline , after 8 weeks. Method of measurement: Realtime PCR.;Serum A-FABP. Timepoint: Baseline , after 8 weeks. Method of measurement: ELISA.;Serum hs-CRP. Timepoint: Baseline , after 8 weeks. Method of measurement: ELISA.;Serum adiponectin. Timepoint: Baseline , after 8 weeks. Method of measurement: ELISA.;Adiponectin / A-FABP. Timepoint: Baseline , after 8 weeks. Method of measurement: Calculate.;Systolic Blood pressure. Timepoint: Baseline , after 8 weeks. Method of measurement: Mercury Sphygmomanometer.;Diastolic Blood pressure. Timepoint: Baseline , after 8 weeks. Method of measurement: Mercury Sphygmomanometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum cratinine. Timepoint: baseline, after 8 weeks. Method of measurement: ELISA.;Waist cirumfrence. Timepoint: baseline, after 8 weeks. Method of measurement: meter.;Hip cirumfrence. Timepoint: baseline, after 8 weeks. Method of measurement: meter.;Serum fasting glucose. Timepoint: baseline, after 8 weeks. Method of measurement: Autoanalyser.;Serum triglyceride. Timepoint: baseline, after 8 weeks. Method of measurement: Autoanalyser.;Serum total cholesterol. Timepoint: baseline, after 8 weeks. Method of measurement: Autoanalyser.;Low density lipoprotein. Timepoint: baseline, after 8 weeks. Method of measurement: Autoanalyser.;High Density Lipoprotein. Timepoint: baseline, after 8 weeks. Method of measurement: Autoanalyser.;Body Composition. Timepoint: baseline, after 8 weeks. Method of measurement: BIA.;Height. Timepoint: Baseline. Method of measurement: meter.;Weight. Timepoint: baseline, after 8 weeks. Method of measurement: Weighing scales.;Body mass index(BMI). Timepoint: baseline, after 8 weeks. Method of measurement: calculate.;24 hours recall. Timepoint: baseline, after 8 weeks. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAtena Ramezani
Depatment of Cellular And Molecular Nutrition, Tehran University of Medical Sciences
Outcome results
None listed